CLINICAL TRIALS PROFILE FOR NAFTIN
✉ Email this page to a colleague
All Clinical Trials for NAFTIN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01580891 ↗ | Evaluate the Clinical Equivalence of Two Naftifine HCl 1% Creams in Patients With Interdigital Tinea Pedis | Completed | Taro Pharmaceuticals USA | Phase 1 | 2012-05-01 | The objective of this study is to evaluate the efficacy and safety of the test formulation of Naftifine HCl Cream 1% (Taro Pharmaceuticals Inc.) as compared to the already marketed formulation Naftin® (Naftifine HCl) 1% Cream (Merz Pharmaceuticals) and placebo in patients with tinea pedis and to show the superiority of the active treatments over placebo when dosed once a day for 28 days. |
| NCT01885156 ↗ | Evaluation of Efficacy and Safety of Naftin 1% Cream in Adolescent Subjects With Tinea Cruris | Completed | Merz North America, Inc. | Phase 3 | 2013-08-01 | To see how well Naftin 1% cream works when applied once daily to the affected area. The results will be compared to those using a placebo cream, which is a cream with no active ingredient. Safety will also be measured. |
| NCT01885156 ↗ | Evaluation of Efficacy and Safety of Naftin 1% Cream in Adolescent Subjects With Tinea Cruris | Completed | Merz Pharmaceuticals, LLC | Phase 3 | 2013-08-01 | To see how well Naftin 1% cream works when applied once daily to the affected area. The results will be compared to those using a placebo cream, which is a cream with no active ingredient. Safety will also be measured. |
| NCT02132260 ↗ | Evaluate the Safety and Efficacy of Naftifine Hydrochloride Cream 2% and Naftin® Cream 2% in Patients With Tinea Pedis | Completed | Taro Pharmaceuticals USA | Phase 1 | 2013-08-01 | The objective of this study is to compare the efficacy and safety of the test formulation of Naftifine Hydrochloride Cream 2% to Naftin® (Naftifine Hydrochloride) 2% Cream in a 6 week study in patients with tinea pedis. |
| NCT02227290 ↗ | Pediatric Subjects With Tinea Corporis | Completed | Merz North America, Inc. | Phase 4 | 2014-08-01 | The study is being done to see how well the study cream works when applied once a day to affected area of child (where they have ringworm). The results will be compared to those seen with a placebo cream which has no active ingredient. Safety of the cream will also be measured. |
| NCT02227290 ↗ | Pediatric Subjects With Tinea Corporis | Completed | Merz Pharmaceuticals, LLC | Phase 4 | 2014-08-01 | The study is being done to see how well the study cream works when applied once a day to affected area of child (where they have ringworm). The results will be compared to those seen with a placebo cream which has no active ingredient. Safety of the cream will also be measured. |
| NCT02335255 ↗ | Evaluate Safety and Efficacy of Naftifine Hydrochloride Gel 2% and Naftin® Gel 2% in Tinea Pedis | Completed | Taro Pharmaceuticals USA | Phase 1 | 2014-06-27 | To compare the efficacy and safety of the test formulation Naftifine Hydrochloride Gel 2% to Naftin® (Naftifine Hydrochloride) Gel 2% |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for NAFTIN
Condition Name
Clinical Trial Locations for NAFTIN
Trials by Country
Clinical Trial Progress for NAFTIN
Clinical Trial Phase
Clinical Trial Sponsors for NAFTIN
Sponsor Name
